Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-501"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"ro"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-501"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-5022
lpv:speaker	lp:Marian-Jean Marinescu2
lpv:spokenAs	substitute; Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN) (2009-09-16--2014-06-30)3 substitute; CONT (2009-07-16--2012-01-18)3 member; TRAN (2009-07-16--2012-01-18)3 substitute; ITRE (2009-07-16--2012-01-18)3 substitute; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3 vice-chair; EPP (2009-11-25--2012-02-02)3 unknown; Partidul Democrat-Liberal (2009-07-14--2014-06-30)3 member; Special committee on the policy challenges and budgetary resources for a sustainable European Union after 2013 (2010-06-17--2011-06-30)3 member; Delegation for relations with Albania, Bosnia and Herzegovina, Serbia, Montenegro and Kosovo (2009-09-16--2014-06-30)3
lpv:translated text	"The pharmaceutical industry is a key sector for the European Union because of both its direct links with the health of every one of us and its economic potential. I believe that the directive and regulation being debated will help improve the system for the supervision of medicinal products. This will facilitate an exchange of information between national and European authorities, which will be in constant contact with patient organisations and representatives from the pharmaceutical industry. Data on adverse drug reactions must not only be accessible to the authorities and healthcare professionals, but to patients as well. Patients must be informed about all the features of the drugs which they are taking and this information must be specified clearly in the patient information leaflet. Patients must be able to identify easily new drugs which have been authorised at a time when all the adverse effects are not yet known and which contain new active substances. Regular monitoring must be carried out and a regular report must be drafted, at least every five years, on the safety of the relevant drugs. Drastic adverse effects can be discovered even 30 years after a drug has been granted market authorisation. Last but not least, I wish to emphasise the interdependence between investment in pharmaceutical research and innovative medical technologies and patient safety and the growth of the pharmaceutical industry."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph